Inhibrx Biosciences Unveils Positive Phase 2 Results for DR5 Agonist Ozekibart in Chondrosarcoma
Inhibrx Biosciences Inc. announced positive Phase 2 results for its DR5 agonist, ozekibart (INBRX-109), in chondrosarcoma. The company will present clinical data at several conferences in November 2025, including the 21st Annual Industry/Academia Precision Oncology & Radmed Symposium and the CTOS 2025 Annual Meeting. The presentations will cover results from the Phase 2 ChonDRAgon study and preclinical data on glioblastoma models. Further details will be available on the company's investor website after each event.
Inhibrx Biosciences Inc., a clinical-stage biopharmaceutical company, has announced upcoming presentations of clinical data related to its novel tetravalent Death Receptor 5 (DR5) agonist, ozekibart (INBRX-109), across several scientific conferences in November 2025. The company will present clinical data on DR5 agonist in chondrosarcoma, colorectal cancer, and Ewing’s sarcoma at the 21st Annual Industry/Academia Precision Oncology & Radmed Symposium on November 5, 2025. Additionally, results from the randomized, registrational, Phase 2 ChonDRAgon study of ozekibart (INBRX-109) in conventional chondrosarcoma will be presented at the Connective Tissue Oncology Society (CTOS) 2025 Annual Meeting on November 14, 2025. Further preclinical data showing anti-tumor activity of ozekibart (INBRX-109) in glioblastoma models, both as monotherapy and in combination with temozolomide (TMZ), will be presented at the CTOS and the Society for NeuroOncology (SNO) 2025 Annual Meeting later in November. The presentations and posters will be made available on the company’s investor website following each event. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Inhibrx Biosciences Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: LA15414) on November 04, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT)
